Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

J Am Heart Assoc. 2023 Sep 19;12(18):e029216. doi: 10.1161/JAHA.122.029216. Epub 2023 Sep 13.
No abstract available

Keywords: PCSK9; cholesterol; safety.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Follow-Up Studies
  • Humans

Substances

  • alirocumab
  • Antibodies, Monoclonal, Humanized

Associated data

  • ClinicalTrials.gov/NCT01663402